Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)

被引:4
作者
Brown, Malcolm [1 ]
Murphy, Marie H. [2 ,3 ]
McAneney, Helen [4 ,5 ]
McBride, Ken [6 ]
Crawford, Ffiona [6 ]
Cole, Aidan [7 ,8 ]
O'Sullivan, Joe M. [7 ,8 ]
Jain, Suneil [7 ,8 ]
Prue, Gillian [1 ]
机构
[1] Queens Univ Belfast, Med Biol Ctr, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Ulster Univ, Ctr Exercise Med Phys Act & Hlth, Sch Sport, Belfast, North Ireland
[3] Univ Edinburgh, Sch Educ & Sport, Edinburgh, Scotland
[4] Ulster Univ, Sch Med, Northern Ireland Publ Hlth Res Network, Belfast, North Ireland
[5] Univ Coll Dublin, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland
[6] Northern Ireland Canc Res Consumer Forum, Belfast, North Ireland
[7] Belfast Hlth & Social Care Trust, Northern Ireland Canc Ctr, Belfast, North Ireland
[8] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland
关键词
Exercise; Feasibility; Metastatic prostate cancer; Functional fitness; Health-related quality of life; QUALITY-OF-LIFE; DEPRIVATION THERAPY; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; PHYSICAL-ACTIVITY; MEN; ENZALUTAMIDE; STRENGTH; MECHANISMS; COUNTRIES;
D O I
10.1007/s00520-023-07894-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundExercise is an effective adjuvant therapy that can alleviate treatment-related toxicities for men with prostate cancer (PC). However, the feasibility of delivering exercise training to men with advanced disease and the wider impact on clinical outcomes remain unknown. The purpose of the EXACT trial was to determine the feasibility and effects of home-based exercise training in men with metastatic castrate-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC receiving ADT + an androgen receptor pathway inhibitor (ARPI) were prescribed 12 weeks of home-based, remotely monitored, moderate intensity, aerobic and resistance exercise. Feasibility was assessed using recruitment, retention and adherence rates. Safety and adverse events were monitored throughout, with functional and patient-reported outcomes captured at baseline, post-intervention and at 3-month follow-up.ResultsFrom the 117 screened, 49 were deemed eligible and approached, with 30 patients providing informed consent (61% recruitment rate). Of those who consented, 28 patients completed baseline assessments, with 24 patients completing the intervention and 22 completing follow-up (retention rates: 86% and 79% respectively). Task completion was excellent throughout, with no intervention-related adverse events recorded. Self-reported adherence to the overall intervention was 82%. Exercise training decreased mean body mass (-1.5%), improved functional fitness (> 10%) and improved several patient-reported outcomes including clinically meaningful changes in fatigue (p = 0.042), FACT-G (p = 0.054) and FACT-P (p = 0.083), all with moderate effect sizes.ConclusionHome-based exercise training, with weekly remote monitoring, was feasible and safe for men with mCRPC being treated with an ARPI. Given that treatment-related toxicities accumulate throughout the course of treatment, and as a result, negatively impact functional fitness and health-related quality of life (HRQoL), it was positive that exercise training improved or prevented a decline in these clinically important variables and could better equip patients for future treatment. Collectively, these preliminary feasibility findings support the need for a definitive, larger RCT, which downstream may lead to the inclusion of home-based exercise training as part of adjuvant care for mCRPC.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer
    Taniguchi, Hisanori
    Ikeda, Junichi
    Masuo, Yuki
    Kinoshita, Hidefumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [32] Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression
    Jin, R.
    Yamashita, H.
    Yu, X.
    Wang, J.
    Franco, O. E.
    Wang, Y.
    Hayward, S. W.
    Matusik, R. J.
    ONCOGENE, 2015, 34 (28) : 3700 - 3710
  • [33] Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
    Kesavan, Murali
    Meyrick, Danielle
    Gallyamov, Marat
    Turner, J. Harvey
    Yeo, Sharon
    Cardaci, Giuseppe
    Lenzo, Nat P.
    DIAGNOSTICS, 2021, 11 (03)
  • [34] Comparing the efficacy of a multi-dimensional breast cancer rehabilitation programme versus a home-based exercise programme during adjuvant cancer treatment
    Chandran, Gobinathan
    Tang, Ning
    Ngo, Ednajoy Lay Poh
    Huang, Serene
    Tong, Shuk In
    Ong, Jie Xin
    Chew, Effie
    BMC CANCER, 2024, 24 (01)
  • [35] Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer
    Del Re, Marzia
    Crucitta, Stefania
    Sbrana, Andrea
    Rofi, Eleonora
    Paolieri, Federico
    Gianfilippo, Giulia
    Galli, Luca
    Falcone, Alfredo
    Morganti, Riccardo
    Porta, Camillo
    Efstathiou, Eleni
    van Schaik, Ron
    Jenster, Guido
    Danesi, Romano
    BJU INTERNATIONAL, 2019, 124 (04) : 693 - 700
  • [36] Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer
    Fettke, Heidi
    Kwan, Edmond M.
    Bukczynska, Patricia
    Ng, Nicole
    Nguyen-Dumont, Tu
    Southey, Melissa C.
    Davis, Ian D.
    Mant, Andrew
    Parente, Phillip
    Pezaro, Carmel
    Hauser, Christine
    Azad, Arun A.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (06): : 1287 - 1291
  • [37] PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
    Shagera, Qaid Ahmed
    Karfis, Ioannis
    Kristanto, Paulus
    Spyridon, Sideris
    Diamand, Romain
    Santapau, Albert
    Peltier, Alexandre
    Roumegue, Thierry
    Flamen, Patrick
    Artigas, Carlos
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1869 - 1875
  • [38] Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies
    Nadal, Rosa
    Tsai, Hua-Ling
    Sinibaldi, Victoria J.
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    Denmeade, Sammuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    PROSTATE, 2016, 76 (05) : 512 - 520
  • [39] Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
    Angelergues, Antoine
    Efstathiou, Eleni
    Gyftaki, Revekka
    Wysocki, Piotr Jan
    Lainez, Nuria
    Gonzalez, Iria
    Castellano, Daniel E.
    Ozguroglu, Mustafa
    Garcia Carbonero, Iciar
    Flechon, Aude
    Borrega, Pablo
    Guillot, Aline
    Campos Balea, Begona
    Le Moulec, Sylvestre
    Esteban, Emilio
    Munarriz, Javier
    Rubio, Gustavo
    Birtle, Alison J.
    Delanoy, Nicolas
    Bellmunt, Joaquim
    Oudard, Stephane
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E777 - E784
  • [40] Effects of home-based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant chemotherapy (SAPA): a randomized controlled trial
    Cornette, Thibault
    Vincent, Francois
    Mandigout, Stephane
    Antonini, Marie-Therese
    Leobon, Sophie
    Labrunie, Anais
    Venat, Laurence
    Lavau-Denes, Sandrine
    Tubiana-Mathieu, Nicole
    EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE, 2016, 52 (02) : 223 - 232